Odyssey Therapeutics, Inc. (ODTX) stock
ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026
$19.37+0.01 (+0.05%)
Close on Nov 17, 2026Market cap $930.89MP/E –Yield –
Odyssey Therapeutics cash
Cash and short-term investments held at the end of each period.
Odyssey Therapeutics's cash was $310.58M at Jun 30, 2026. For fiscal 2025 it was $181.36M, up 190.9% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $181.36M | +190.9% |
| FY2024 | Dec 31, 2024 | $62.35M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $310.58M | +465.6% |
| Q1 FY2026 | Mar 31, 2026 | $175.75M | +181.9% |
| Q4 FY2025 | Dec 31, 2025 | $181.36M | – |
| Q2 FY2025 | Jun 30, 2025 | $163.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $54.91M | – |
| Q4 FY2024 | Dec 31, 2024 | $62.35M | – |
See a number that looks wrong?